ライフサイエンスコーパス: percutaneous transluminal angioplasty

1 oons in patients undergoing femoro-popliteal percutaneous transluminal angioplasty.

2 rug-eluting stents over bare metal stents or percutaneous transluminal angioplasty alone, particularl

3 was smaller in the medical group versus the percutaneous transluminal angioplasty and stenting (PTAS

4 roke that is increasingly being treated with percutaneous transluminal angioplasty and stenting (PTAS

5 RECENT FINDINGS: Percutaneous transluminal angioplasty and stenting is a

6 and D lesions are not randomized and receive percutaneous transluminal angioplasty and stenting or fe

7 to receive either femoropopliteal bypass or percutaneous transluminal angioplasty and stenting; pati

8 Contemporary studies of the use of percutaneous transluminal angioplasty as primary treatme

9 Two balloon (percutaneous transluminal angioplasty) catheters were us

10 porary studies (2005-2015) on the effects of percutaneous transluminal angioplasty for the treatment

11 Contemporary outcomes of percutaneous transluminal angioplasty for the treatment

12 lloon angioplasty group and the conventional percutaneous transluminal angioplasty group had similar

13 l rates through 12 months were higher in the percutaneous transluminal angioplasty group.

14 At many institutions, percutaneous transluminal angioplasty has become the tre

15 Peripheral percutaneous transluminal angioplasty is fraught with a

16 treatment of peripheral artery disease with percutaneous transluminal angioplasty is limited by the

17 ctory angina pectoris when bypass surgery or percutaneous transluminal angioplasty is not indicated.

18 Standard percutaneous transluminal angioplasty is the current rec

19 oved the likelihood of technical success for percutaneous transluminal angioplasty of dialysis access

20 ents, mortality, and clinical progression to percutaneous transluminal angioplasty or loss of patency

21 and publication bias were observed for most percutaneous transluminal angioplasty outcomes.

22 After successful high-pressure percutaneous transluminal angioplasty, participants were

23 of a paclitaxel DCB (n = 1,837) and uncoated percutaneous transluminal angioplasty (PTA) (n = 143) we

24 f patients with critical limb ischemia using percutaneous transluminal angioplasty (PTA) and bail-out

25 l restenosis and reintervention rates versus percutaneous transluminal angioplasty (PTA) and improve

26 The RCT compared the DES with percutaneous transluminal angioplasty (PTA) and provisio

27 treatment with a low-dose DCB or an uncoated percutaneous transluminal angioplasty (PTA) balloon.

28 dy of mature accesses that underwent balloon percutaneous transluminal angioplasty (PTA) between Janu

29 ngioplasty (DCBA) compared with conventional percutaneous transluminal angioplasty (PTA) for below-th

30 el drug-eluting balloons versus conventional percutaneous transluminal angioplasty (PTA) for the redu

31 We compared a paclitaxel-coated balloon with percutaneous transluminal angioplasty (PTA) for the trea

32 ed balloon (DCB) angioplasty versus standard percutaneous transluminal angioplasty (PTA) in patients

33 Percutaneous transluminal angioplasty (PTA) is the stand

34 Percutaneous transluminal angioplasty (PTA) of stenotic

35 eserved for lesions that are not amenable to percutaneous transluminal angioplasty (PTA) or for recur

36 Use of a covered stent after percutaneous transluminal angioplasty (PTA) was compared

37 runs were higher (all P<.001) than those for percutaneous transluminal angioplasty (PTA), as were rad

38 study was to compare long-term outcomes with percutaneous transluminal angioplasty (PTA), stent place

39 To compare mortality after DCB or uncoated percutaneous transluminal angioplasty (PTA), we aggregat

40 e 1-year outcomes compared with conventional percutaneous transluminal angioplasty (PTA), yet durabil

41 t has improved the patency rate of SFA after percutaneous transluminal angioplasty (PTA).

42 eal changes in renal function at the time of percutaneous transluminal angioplasty (PTA).

43 d Trial of IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty [PTA] Balloon Cath

44 gned to DCB (n=200) or standard angioplasty (percutaneous transluminal angioplasty [PTA]) (n=100).

45 Alleviating vascular restenosis after percutaneous transluminal angioplasty remains a formidab

46 r interventions include balloon angioplasty (percutaneous transluminal angioplasty [standard], drug-c

47 (2 with subclavian-carotid bypass and 5 with percutaneous transluminal angioplasty stenting of the su

48 , and reinterventions after femoro-popliteal percutaneous transluminal angioplasty up to 1 year of fo

49 o has successfully undergone angiography and percutaneous transluminal angioplasty using CO2 as the s

50 Percutaneous transluminal angioplasty was then performed

51 popliteal atherosclerotic disease undergoing percutaneous transluminal angioplasty were randomized to

52 c femoropopliteal peripheral artery disease, percutaneous transluminal angioplasty with a paclitaxel-